Filter Results:
(6)
Show Results For
- All HBS Web (13)
- Faculty Publications (2)
Show Results For
- All HBS Web (13)
- Faculty Publications (2)
Page 1 of 6
Results
Sort by
- 2015
- Working Paper
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
By: Pierre Azoulay, Joshua S. Graff Zivin, Danielle Li and Bhaven N. Sampat
We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly... View Details
Keywords: Economics Of Science; Patenting; Academic Reserach; NIH; Knowledge Spillovers; Patents; Research; Government and Politics
Azoulay, Pierre, Joshua S. Graff Zivin, Danielle Li, and Bhaven N. Sampat. "Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules." Harvard Business School Working Paper, No. 16-056, October 2015.
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- 2015
- Working Paper
Expertise vs. Bias in Evaluation: Evidence from the NIH
By: Danielle Li
Evaluators with expertise in a particular field may have an informational advantage in separating good projects from bad. At the same time, they may also have personal preferences that impact their objectivity. This paper develops a framework for separately identifying... View Details
Li, Danielle. "Expertise vs. Bias in Evaluation: Evidence from the NIH." Harvard Business School Working Paper, No. 16-053, October 2015.
- 03 Nov 2015
- First Look
November 3, 2015
successfully navigate their academic careers. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=50056 Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules By: Azoulay, Pierre, Joshua S.... View Details
Keywords: Sean Silverthorne
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
million to $5 million, with most of that money coming from grants from institutions like the National Institutes of Health (NIH). “Funding can be canceled with the stroke of a pen.” The NIH allocates money to researchers whose proposals... View Details
- 28 Nov 2016
- Research & Ideas
Challenging the Belief that Liability Laws Kill Medical Device Innovation
bottom line of medical device companies—it’s good for patients as well. Related Reading: New Medical Devices Get To Patients Too Slowly Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules Five... View Details